A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Status:
Recruiting
Trial end date:
2023-03-20
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and
safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing
tumors.
This study will enroll 7 tumor-specific cohorts: urothelial bladder cancer, biliary tract
cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare
tumors.
Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a
favorable risk benefit profile in selected HER2-expressing solid tumors.